Sai Life Sciences IPO price band is fixed at ₹522 to ₹549 per share. At the upper-end of the price band, the company plans to ...

According to market observers, shares of the company are available at a premium of ₹18 in the grey market today ...

The IPO received strong demand from qualified institutional buyers (QIBs). The current grey market premium (GMP) of the IPO ...

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and ...

科罗拉多州威斯敏斯特市—TriSalus Life Sciences, Inc. (NASDAQ:TLSI)的董事Arjun JJ Desai最近出售了30,000股公司普通股。根据SEC文件报告，这笔交易发生于2024年12月10日，总价值约为110,700美元。

Sai Life Sciences' Rs 3,042 crore IPO was oversubscribed 1.25 times on its second day, driven by institutional investors. The ...

Sai Life Sciences Ltd.'s initial public offering entered its final day for subscription on Friday. It was subscribed 1.65 ...

Sai Life Sciences Ltd's Rs 3,043-crore IPO saw a remarkable 10.26 times subscription on the final day. The company's shares ...

北京时间2024年12月11日00时42分，Atai Life Sciences N.V.（ATAI.us）股票出现波动，股价大幅下跌5.03%。截至发稿，该股报1.51美元/股，成交量44.4207万股， 换手率 0.26%，振幅5.03%。

Today is the third and last day for the initial public offering (IPO) of contract research, development, and manufacturing ...

在其他最近的新闻中，SELLAS Life Sciences Group报告了其针对急性髓系白血病患者的SLS009药物二期临床试验的有希望结果。患者的中位总生存期现已超过7.7个月，相比历史预期的2.5个月有显著改善。两个扩展队列的总体响应率也超过了33%的目标响应率，达到56%。这些令人鼓舞的结果导致 InvestingPro 的分析师上调了盈利预期。

北京时间2024年12月04日01时48分，Atai Life Sciences N.V.（ATAI.us）股票出现波动，股价急速下挫5.03%。截至发稿，该股报1.61美元/股，成交量68.9255万股， 换手率 0.41%，振幅4.14%。